CESCA Therapeutics to Present at the 2017 International Symposium of Translational Medicine in Stem Cell Myocardial Repair
April 11 2017 - 7:15AM
Cesca Therapeutics Inc. (Nasdaq:KOOL), a market leader in automated
cell processing and point-of-care, autologous cell-based therapies,
today announced that Dr. Xiaochun (Chris) Xu, Chairman and Interim
Chief Executive Officer and Chairman of Boyalife Group, will
present an overview of the Company’s cardiovascular clinical
research program at the 2017 International Symposium of
Translational Medicine in Stem Cell Myocardial Repair, being held
April 10-12, 2017 at the Hope Hotel in Shanghai, China.
Details of the presentation are as follows:
Title: |
Autologous Stem Cell
Applications in Critical Limb Ischemia and Myocardial
Infarction |
Session: |
Stem Cells and Tissue
Engineering in Preclinical Studies |
Location: |
Hope Hotel, Chengxia
Room, 5th Floor |
Date: |
Wednesday, April 12,
2017 |
Time: |
4:40pm – 5:00pm
CST |
“Despite recent therapeutic and surgical
advances, the effects of peripheral arterial disease, including
heart attack and critical limb ischemia (CLI), remain among the
world’s leading causes of morbidity and mortality and represent a
rapidly escalating public health crisis,” noted Dr. Xu. “I look
forward to presenting a review of our latest findings, including
key feasibility study results and an overview of our Phase 3
Critical Limb Ischemia Rapid Stemcell Treatment (CLIRST) trial,
which we believe highlight the potential of Cesca Therapeutics’
proprietary AutoXpress® point-of-care platform to deliver
autologous cell-based therapies that may represent a new paradigm
in patient treatment going forward.”
About the Symposium of Translational
Medicine in Stem Cell Myocardial Repair
The 2017 International Symposium of
Translational Medicine in Stem Cell Myocardial Repair brings
together more than 650 of the world’s cardiac disease thought
leaders to discuss the potential of translational and regenerative
medicine in treating myocardial infarction (MI) and cardiac
failure. The symposium is co-sponsored by the Shanghai Society for
Cell Biology, the Institute of Health Sciences, the Shanghai
Cardiovascular Disease Institute, the Guangzhou Institutes of
Biomedicine and Health, and the Key Laboratory of Stem Cell
Biology, Shanghai.
About Cesca Therapeutics Inc.
Cesca is engaged in the research, development,
and commercialization of cellular therapies and delivery systems
for use in regenerative medicine. The Company is a leader in the
development and manufacture of automated blood and bone marrow
processing systems that enable the separation, processing and
preservation of cell and tissue therapeutics. Cesca is an affiliate
of the Boyalife Group (http://www.boyalifegroup.com), a China-based
industrial-research alliance among top research institutes for stem
cell and regenerative medicine.
Forward-Looking Statement
The statements contained herein may include
statements of future expectations and other forward-looking
statements that are based on management’s current views and
assumptions and involve known and unknown risks and uncertainties
that could cause actual results, performance or events to differ
materially from those expressed or implied in such statements. A
more complete description of risks that could cause actual events
to differ from the outcomes predicted by Cesca Therapeutics'
forward-looking statements is set forth under the caption "Risk
Factors" in Cesca Therapeutics annual report on Form 10-K and other
reports it files with the Securities and Exchange Commission from
time to time, and you should consider each of those factors when
evaluating the forward-looking statements.
Company Contact: Cesca Therapeutics Inc.
ir@cescatherapeutics.com
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
pschwartz@rxir.com
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Apr 2023 to Apr 2024